Sponsor Pipeline

Gruppo Oncologico del Nord-Ovest Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
19
Active Trials
9
Recruiting
4
Phase 3
4
Disease Areas
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-08-13 NCT07763171 Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and… Phase 3 Not Yet Recruiting
Active Trials by Phase
Phase 4
1
Phase 3
3
Phase 2/3
1
Phase 2
13
Phase 1/2
1
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT07094893 Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type… Colorectal Cancer Not Yet Recruiting
Phase 3
NCT06897644 Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified… Pancreatic Adenocarcinoma Advanced or Metastatic Recruiting
NCT06733038 FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and… Colorectal Cancer Recruiting
NCT07763171 Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and… Gastroesophageal Adenocarcinoma Not Yet Recruiting
Phase 2/3
NCT06037980 CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus… Biliary Tract Cancer Recruiting
Phase 2
NCT04681469 Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative… Head and Neck Squamous Cell Carcinoma Recruiting
NCT06253650 Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With… Gastric Cancer Recruiting
NCT06869473 Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and… Head and Neck Squamous Cell Carcinoma (HNSCC) Recruiting
NCT07407465 Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2… Colorectal Cancer Recruiting
NCT05845450 Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer… Colorectal Cancer Recruiting
NCT07485296 Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as… Head & Neck Squamous Cell Carcinoma Recruiting
NCT04817826 TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable… Gastric Cancer Active, Not Recruiting
NCT06578559 Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF… Colorectal Cancer Active, Not Recruiting
NCT05594290 Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery Merkel Cell Carcinoma Active, Not Recruiting
NCT04787341 PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence Colorectal Cancer Active, Not Recruiting
NCT04806646 Tailored Sonidegib Schedule After Complete Response in BCC Locally Advanced Basal Cell Carcinoma Active, Not Recruiting
NCT04825990 Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal… Nasopharyngeal Carcinoma Active, Not Recruiting
NCT05253846 Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29 Locally Advanced Rectal Cancer Active, Not Recruiting
Phase 1/2
NCT04564898 Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic… Colorectal Cancer Metastatic Active, Not Recruiting
Disease Areas
Get alerts when Gruppo Oncologico del Nord-Ovest's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free